Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Creating “blockbuster” potential drugs, from deuterium chemistry tech

March 14, 2019 admin CEO Interview, Healthcare Comments Off on Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Creating “blockbuster” potential drugs, from deuterium chemistry tech

 

Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential!
Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of the crowd.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

Roger Tung, CEO

 

 

 

 

 

 

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Interview with Roger Tung, CEO discussing the company’s deuterium chemistry platform for creating new drugs which have superior properties—including enhanced clinical safety, tolerability or efficacy—based on compounds that have established pharmacological activity. The company’s current pipeline has 3 drugs which have “blockbuster potential” for treating, alopecia areata,  schizophrenia, and Alzheimers agitation. 

Investor Presentation

Concert-Presentation-Feb2019-FINAL

 




Related Articles

Healthcare

Zylo and Hoth Therapeutics (NASDAQ: HOTH) Forge Partnership to Develop Endocannabinoid-Based Drug to Treat Lupus

August 29, 2019 admin Healthcare, Newsmakers Comments Off on Zylo and Hoth Therapeutics (NASDAQ: HOTH) Forge Partnership to Develop Endocannabinoid-Based Drug to Treat Lupus

Greenville, SC, Aug. 22, 2019 — Zylo Therapeutics, dedicated to bringing innovative topical technologies to multiple facets of medicine, has entered into a definitive partnership agreement with Hoth Therapeutics (NASDAQ: HOTH) to develop a new treatment for […]

CEO Interview

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

October 17, 2018 admin CEO Interview, Healthcare Comments Off on Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

  Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. Join over 100,000 investors and business leaders worldwide. Discover the Next Super Stock before the rest of […]

Healthcare

Patient Treated with Leronlimab (PRO 140) for Metastatic Triple-Negative Breast Cancer under Emergency IND, Launching CytoDyn (OTC: CYDY) into Oncology

August 6, 2019 admin Healthcare, Newsmakers Comments Off on Patient Treated with Leronlimab (PRO 140) for Metastatic Triple-Negative Breast Cancer under Emergency IND, Launching CytoDyn (OTC: CYDY) into Oncology

VANCOUVER, Washington, Aug. 06, 2019 – CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the […]